Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

NFKBIA deletion in glioblastomas.

Bredel M, Scholtens DM, Yadav AK, Alvarez AA, Renfrow JJ, Chandler JP, Yu IL, Carro MS, Dai F, Tagge MJ, Ferrarese R, Bredel C, Phillips HS, Lukac PJ, Robe PA, Weyerbrock A, Vogel H, Dubner S, Mobley B, He X, Scheck AC, Sikic BI, Aldape KD, Chakravarti A, Harsh GR 4th.

N Engl J Med. 2011 Feb 17;364(7):627-37. doi: 10.1056/NEJMoa1006312. Epub 2010 Dec 22.

2.

Frequency of NFKBIA deletions is low in glioblastomas and skewed in glioblastoma neurospheres.

Patanè M, Porrati P, Bottega E, Morosini S, Cantini G, Girgenti V, Rizzo A, Eoli M, Pollo B, Sciacca FL, Pellegatta S, Finocchiaro G.

Mol Cancer. 2013 Dec 11;12:160. doi: 10.1186/1476-4598-12-160.

3.

NFKBIA deletion in glioblastomas.

Idbaih A, Marie Y, Sanson M.

N Engl J Med. 2011 Jul 21;365(3):277; author reply 277-8. doi: 10.1056/NEJMc1103354. No abstract available.

PMID:
21774727
4.

Alteration in NFKBIA and EGFR in glioblastoma multiforme.

Komotar RJ, Starke RM, Connolly ES, Sisti MB.

Neurosurgery. 2011 Jun;68(6):N14-5. doi: 10.1227/01.neu.0000398206.71573.50. Review. No abstract available.

PMID:
21778941
5.

Identification of a NFKBIA polymorphism associated with lower NFKBIA protein levels and poor survival outcomes in patients with glioblastoma multiforme.

Zhao Z, Zhong X, Wu T, Yang T, Chen G, Xie X, Wei Y, Ye M, Zhou Y, Du Z.

Int J Mol Med. 2014 Nov;34(5):1233-40. doi: 10.3892/ijmm.2014.1932. Epub 2014 Sep 12.

6.

Monosomy of chromosome 10 associated with dysregulation of epidermal growth factor signaling in glioblastomas.

Yadav AK, Renfrow JJ, Scholtens DM, Xie H, Duran GE, Bredel C, Vogel H, Chandler JP, Chakravarti A, Robe PA, Das S, Scheck AC, Kessler JA, Soares MB, Sikic BI, Harsh GR, Bredel M.

JAMA. 2009 Jul 15;302(3):276-89. doi: 10.1001/jama.2009.1022.

7.

NFKBIA deletion in glioblastomas.

Takeuchi S, Nawashiro H.

N Engl J Med. 2011 Jul 21;365(3):276-7; author reply 277-8. doi: 10.1056/NEJMc1103354. No abstract available.

8.

Silenced expression of NFKBIA in lung adenocarcinoma patients with a never-smoking history.

Furukawa M, Soh J, Yamamoto H, Ichimura K, Shien K, Maki Y, Muraoka T, Tanaka N, Ueno T, Asano H, Tsukuda K, Toyooka S, Miyoshi S.

Acta Med Okayama. 2013;67(1):19-24.

9.

Primary glioblastomas with and without EGFR amplification: relationship to genetic alterations and clinicopathological features.

Benito R, Gil-Benso R, Quilis V, Perez M, Gregori-Romero M, Roldan P, Gonzalez-Darder J, Cerdá-Nicolas M, Lopez-Gines C.

Neuropathology. 2010 Aug;30(4):392-400. doi: 10.1111/j.1440-1789.2009.01081.x. Epub 2009 Dec 16.

PMID:
20051017
10.

Prognostic impact of molecular markers in a series of 220 primary glioblastomas.

Houillier C, Lejeune J, Benouaich-Amiel A, Laigle-Donadey F, Criniere E, Mokhtari K, Thillet J, Delattre JY, Hoang-Xuan K, Sanson M.

Cancer. 2006 May 15;106(10):2218-23.

11.

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute DJ, Riggs BL, Horvath S, Liau LM, Cavenee WK, Rao PN, Beroukhim R, Peck TC, Lee JC, Sellers WR, Stokoe D, Prados M, Cloughesy TF, Sawyers CL, Mischel PS.

N Engl J Med. 2005 Nov 10;353(19):2012-24. Erratum in: N Engl J Med. 2006 Feb 23;354(8):884.

12.
13.

A prognostic analysis of pediatrics central nervous system small cell tumors: evaluation of EGFR family gene amplification and overexpression.

Liu W, Zhang S, Zhang L, Cui Q, Wang J, Gui T, Pang Q.

Diagn Pathol. 2014 Jul 1;9:132. doi: 10.1186/1746-1596-9-132.

14.

Glioblastoma stem-like cell lines with either maintenance or loss of high-level EGFR amplification, generated via modulation of ligand concentration.

Schulte A, Günther HS, Martens T, Zapf S, Riethdorf S, Wülfing C, Stoupiec M, Westphal M, Lamszus K.

Clin Cancer Res. 2012 Apr 1;18(7):1901-13. doi: 10.1158/1078-0432.CCR-11-3084. Epub 2012 Feb 7.

16.

Paradoxical relationship between the degree of EGFR amplification and outcome in glioblastomas.

Hobbs J, Nikiforova MN, Fardo DW, Bortoluzzi S, Cieply K, Hamilton RL, Horbinski C.

Am J Surg Pathol. 2012 Aug;36(8):1186-93. doi: 10.1097/PAS.0b013e3182518e12.

17.

Mutations of TP53, amplification of EGFR, MDM2 and CDK4, and deletions of CDKN2A in malignant astrocytomas.

Biernat W, Debiec-Rychter M, Liberski PP.

Pol J Pathol. 1998;49(4):267-71.

PMID:
10323080
18.

Magnetic resonance imaging characteristics predict epidermal growth factor receptor amplification status in glioblastoma.

Aghi M, Gaviani P, Henson JW, Batchelor TT, Louis DN, Barker FG 2nd.

Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8600-5.

19.

Deletion and low expression of NFKBIA are associated with poor prognosis in lower-grade glioma patients.

Kinker GS, Thomas AM, Carvalho VJ, Lima FP, Fujita A.

Sci Rep. 2016 Apr 7;6:24160. doi: 10.1038/srep24160.

20.

Glioblastomas with IDH1/2 mutations have a short clinical history and have a favorable clinical outcome.

Ohno M, Narita Y, Miyakita Y, Matsushita Y, Arita H, Yonezawa M, Yoshida A, Fukushima S, Takami H, Ichimura K, Shibui S.

Jpn J Clin Oncol. 2016 Jan;46(1):31-9. doi: 10.1093/jjco/hyv170. Epub 2015 Nov 24.

PMID:
26603354

Supplemental Content

Support Center